Metoclopramide modelling study sharpens bolus-versus-CRI decisions: full analysis

A newly published Journal of Small Animal Practice study puts a familiar ICU and internal medicine drug back under the microscope. In “Bolus and infusions of metoclopramide: insights on benefits and risks from pharmacokinetic modelling,” researchers reanalyzed canine pharmacokinetic data to test how metoclopramide behaves when delivered as a constant-rate infusion, either alone or with a loading dose. Their central message is straightforward: if the goal is to reach target plasma concentrations right away, infusion alone may be too slow, and a bolus can materially change early exposure. The paper appeared in JSAP on May 25, 2026. (vetlit.org)

That question matters because metoclopramide sits in an awkward but important place in small animal practice. It’s widely used as both an antiemetic and an upper GI prokinetic in dogs, yet standard dosing remains more convention than precision. Merck Veterinary Manual lists IV infusion dosing in dogs and cats at 0.01 to 0.02 mg/kg/h, while a recent Today’s Veterinary Practice review says the “ideal dose” is still unknown, noting that many clinicians start with a CRI of 2 mg/kg/day and may give a 0.5 mg/kg bolus first. That same review also points out that some studies suggest these commonly used doses may be inadequate for prokinetic effect in some dogs. (merckvetmanual.com)

The background here is that metoclopramide’s pharmacology is useful, but its clinical window may be narrower than day-to-day use sometimes implies. The drug antagonizes dopamine receptors centrally and acts peripherally on serotonergic pathways, increasing coordinated motility in the esophagus, stomach, pylorus, and duodenum. It’s used for chemotherapy-associated vomiting, reflux, and postoperative ileus, but it also crosses the blood-brain barrier, which is why dose escalation can bring CNS adverse effects. Merck specifically warns about extrapyramidal signs including involuntary muscle spasms, motor restlessness, and inappropriate aggression. (merckvetmanual.com)

Against that backdrop, the new paper appears to offer a more quantitative framework for a question clinicians face often: is it better to start a CRI and wait, or to give a bolus and accept the possibility of transiently higher concentrations? Based on the study abstract and journal listing, the authors used previously collected dog data to simulate constant-rate infusion regimens with and without loading doses and to determine loading doses capable of achieving target plasma concentrations immediately. That makes the paper less about proving efficacy in a new disease population and more about sharpening dose design around time-to-target and safety. (vetlit.org)

There’s already some clinical context suggesting why that tradeoff matters. A 2025 practical review on ileus says metoclopramide is commonly administered by CRI, often after a 0.5 mg/kg IV bolus, and that clinicians may titrate upward when hypomotility persists. But the same review warns that high doses can trigger aggression, restlessness, hypersalivation, and muscle rigidity. Older canine work has also linked high-dose metoclopramide infusions during anesthesia with reduced gastroesophageal reflux risk, underscoring that stronger exposure may improve effect, even if tolerability becomes the limiting factor. (todaysveterinarypractice.com)

For veterinary professionals, the practical takeaway is that this is the kind of paper that could influence inpatient protocols more than formularies. Metoclopramide is not new, but the modelling may help teams think more deliberately about initiation strategy, especially in hospitalized dogs where clinicians want prokinetic or antiemetic benefit without delay. A loading dose may be attractive in patients with active regurgitation, suspected upper GI hypomotility, or postoperative ileus, but the paper also reinforces that “more” isn’t automatically “better.” Mechanical obstruction still has to be ruled out before prokinetic use, and any effort to push concentrations higher has to be weighed against neurologic adverse effects and patient-to-patient variability. (merckvetmanual.com)

Industry or outside expert reaction specific to this paper was limited at the time of writing, but the broader professional conversation is already aligned with its premise: metoclopramide remains useful, dosing is still imperfect, and response can be inconsistent. The Today’s Veterinary Practice review explicitly says optimal dosing in dogs and cats has not been identified and may need to be adjusted to the individual patient. In that sense, the new JSAP study adds evidence to an existing clinical reality rather than overturning it. (todaysveterinarypractice.com)

Why it matters: For hospitals, referral services, and general practices managing complex GI cases, this paper may help move metoclopramide use from habit-based dosing toward concentration-informed dosing. Even if the study is modelling-based rather than outcomes-based, it gives clinicians a better rationale for when a bolus is likely to help, and when it may simply add risk. That’s especially relevant in dogs receiving multiple CNS-active drugs, in brachycephalic reflux cases, and in postoperative patients where teams are trying to balance nausea control, motility support, and smooth recovery. (vetlit.org)

What to watch: The next step is prospective clinical validation: whether the model-derived loading strategies improve vomiting control, reflux prevention, gastric emptying, or ileus outcomes in real canine patients, and whether particular subgroups end up needing different starting doses. (vetlit.org)